6 unknown, 4 completed, 1 suspended, 1 terminated. 7 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 4, Completed 2, Suspended 1 |
| Phase 1 | 6 | Unknown 3, Completed 2, Terminated 1 |
| Phase 3 | 2 | Unknown 1, Withdrawn 1 |
Follow abivertinib: new trials by email Literature Review of abivertinib trials Research Report on abivertinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer Abivertinib, Abiraterone - Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Suspended | Sorrento Therapeutics, Inc. | 100 | 2025-09-01 | 2024-03-18 |
| Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 STI-5656, Placebo - Covid19 | Phase 2 | Completed | Sorrento Therapeutics, Inc. | 396 | 2021-01-06 | 2021-11-03 |
| Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19 Abivertinib, Standard of Care - Covid-19 | Phase 2 | Completed | Sorrento Therapeutics, Inc. | 96 | 2020-10-09 | 2023-01-18 |
| Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation Abivertinib Maleate Capsules, Placebo Gefitinib Tablets, Gefitinib Tablets - Advanced Non-small Cell Lung Cancer | Phase 3 | Unknown | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 406 | 2019-03-01 | 2019-02-27 |
| A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI Pemetrexed, Cisplatin 75mg/m2, AC0010 - NSCLC | Phase 3 | Withdrawn | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2018-12-01 | 2019-02-04 | |
| Phase II Umbrella Study Directed by Next Generation Sequencing Avitinib Maleate, Afatinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Guangdong Association of Clinical Trials | 400 | 2018-07-09 | 2022-12-06 |
| Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC AC0010 - Metastatic Non-small Cell Lung Cancer | Phase 2 | Unknown | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 222 | 2017-05-18 | 2019-02-19 |
| A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL AC0010MA - B-cell Lymphoma | Phase 1 | Unknown | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 184 | 2017-03-17 | 2019-02-01 |
| Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment AC0010 - Carcinoma，Non-Small-Cell Lung | Phase 1 | Completed | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 7 | 2016-11-01 | 2019-02-01 |
| Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC AC0010 - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 7 | 2016-11-01 | 2017-10-03 |
| Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer AC0010MA - Non Small Cell Lung Cancer | Phase 1 | Terminated | ACEA Therapeutics, Inc. | 28 | 2015-05-01 | 2019-10-29 |
| Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC AC0010 - Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 368 | 2015-01-01 | 2021-09-10 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer AC0010 - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 100 | 2014-09-01 | 2016-11-23 |
Carcinoma, Non-Small-Cell Lung (7) · COVID-19 (2) · Lymphoma, B-Cell (1) · Prostatic Neoplasms (1)
Hangzhou ACEA Pharmaceutical Research Co., Ltd. (7) · Sorrento Therapeutics, Inc. (3) · ACEA Therapeutics, Inc. (1) · Guangdong Association of Clinical Trials (1) · Sun Yat-sen University (1)
China (9) · United States (3) · Brazil (1) · France (1) · Spain (1)
Mike Royal, MD (2) · Yilong Wu, MD (2) · Feng Shao, Doctor (1) · Heather Wakelee, MD (1) · Jie Jin, MD (1) · Karen L Reckamp, MD (1) · Li Zhang, professor (1) · Lihua Bao, Doctor (1) · Lingxiang Liu, Doctor (1) · Mike Royal, MD JD (1) · Suresh S. Ramalingam, MD (1) · Vali A. Papadimitrakopoulou, MD (1) · Yi-Long Wu (1) · Yilong Wu, MD. (1) · Yongqian Shu, Doctor (1)